Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation, doing business as NPS, supplies specialty pharmaceutical and radiopharmaceutical products to federal healthcare agencies as a prime contractor under full-and-open competition (no set-asides), with a heavy concentration of recent delivery orders to the Department of Veterans Affairs across multiple regional service networks. Novartis is a foreign-owned, for-profit manufacturer headquartered in East Hanover, New Jersey, competing directly in the federal market under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC category Drugs and Biologicals.

The vendor's federal portfolio centers on three core product lines: PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate), both radiopharmaceutical therapies for advanced cancers (metastatic castration-resistant prostate cancer and neuroendocrine tumors, respectively); FABHALTA, an oral antigen-directed therapy for autoimmune conditions; and supporting diagnostic and supportive products including NETSPOT and LOCAMETZ. Recent representative prime awards include a $5.37 million Defense Health Agency delivery order issued October 1, 2026, for LUTATHERA and PLUVICTO under a single-award Indefinite Delivery Contract; a $4.3 million Veterans Integrated Service Network 22 delivery order for PLUVICTO and LUTATHERA under the FSS-61-IB schedule (November 1, 2025); a $3.99 million VISN 21 delivery order for PLUVICTO (October 1, 2025); and recurring small-volume FABHALTA orders across multiple VISNs averaging roughly $34,000 per delivery order.

Customer concentration is extreme: the Department of Veterans Affairs Veterans Integrated Service Network 12 accounts for 69 awards and $23.87 billion combined potential value (98% of the portfolio's total value), anchorlike dominance that reflects a single large master contract or platform agreement. The broader VA ecosystem — National Acquisition Center, VISN 10, VISN 21, and others — contributes an additional $205 million. The Defense Health Agency holds ten awards worth $44.7 million. The Defense Logistics Agency, while placing 208 awards (the highest by count), appears to represent older, lower-value activity; the portfolio's most recent high-volume customer activity concentrates at VA VISNs.

Novartis holds multiple vehicle positions anchoring federal access. The National Acquisition Center issued a $61.084 million Blanket Purchase Agreement (October 2, 2025, through October 1, 2027) for KYMRIAH, FABHALTA, NETSPOT, and LOCAMETZ under FSS-61-IB (Pharmaceuticals and Drugs Federal Supply Schedule). The Defense Health Agency awarded a $26.1 million single-award Indefinite Delivery Contract (October 1, 2024, through September 30, 2029) for LUTATHERA and PLUVICTO with firm fixed-price line items. Veterans Integrated Service Network 10 established a $7.48 million Blanket Purchase Agreement (October 1, 2025, through September 30, 2030) for PLUVICTO. The Defense Health Agency also holds a $5.0 million single-award BPA (March 2, 2026, through February 9, 2031) for PLUVICTO and LUTATHERA. The parent GSA Federal Supply Schedule vehicle (FSS-61-IB) carries 95 task orders worth $248.3 million combined value. Older Defense Logistics Agency BOAs (DLA12089D0449, DLA12085D0418, DLA12087D0086) show prior activity but do not feature in recent ordering.

Activity has accelerated sharply: four awards in 2021 to 35 in 2025 and 28 in 2026. Fifteen awards (combined potential value $28.4 million) reach ultimate completion within the next twenty-four months and face recompete risk. The vendor's actual invoiced obligations total $116.5 million against a potential-value portfolio of $24.43 billion — a 0.5% drawdown rate characteristic of indefinite delivery vehicles early in their performance period.

Place of performance spans Novartis' nationwide manufacturing and distribution network: East Hanover, New Jersey (headquarters); Cary, North Carolina; Lake Mary, Florida; Phoenix, Arizona; Lebanon, Pennsylvania; Chicago, Illinois; San Antonio, Texas; West Haven, Connecticut; and Bethesda, Maryland, with delivery to military treatment facilities, VA medical centers, and federal healthcare beneficiary locations.